SARS-CoV-2 neutralizing antibodies after first vaccination dose in breast cancer patients receiving CDK4/6 inhibitors

Commentary: SARS-CoV-2 vaccines and cancer patients

(2021) C. Corti et al.   ANNALS OF ONCOLOGY

Looking beyond COVID-19 vaccine phase 3 trials

(2021) Jerome H. Kim et al.   NATURE MEDICINE

COVID‐19 risk in breast cancer patients receiving CDK4/6 inhibitors: literature data and a monocentric experience

(2021) Maddalena Barba et al.   Breast Journal

Age‐dependent and gender‐dependent antibody responses against SARS‐CoV ‐2 in health workers and octogenarians after vaccination with the BNT162b2 mRNA vaccine

(2021) Evangelos Terpos et al.   AMERICAN JOURNAL OF HEMATOLOGY

97P Is continuing CDK4-6 inhibitor therapy safe during the COVID-19 pandemic? A UK cancer centre experience

(2021) V. Angelis et al.   ANNALS OF ONCOLOGY

Low titers of SARS-CoV-2 neutralizing antibodies after first vaccination dose in cancer patients receiving checkpoint inhibitors

(2021) Evangelos Terpos et al.   Journal of Hematology & Oncology

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

(2020) Nicole M Kuderer et al.   LANCET

A Protracted Course of COVID19 Infection in a Metastatic Breast Cancer Patient During CDK4/6 Inhibitor Therapy

(2020) Albert Grinshpun et al.   Frontiers in Oncology

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

(2020) Edward E. Walsh et al.   NEW ENGLAND JOURNAL OF MEDICINE

CDK4/6 inhibitors in breast cancer: differences in toxicity profiles and impact on agent choice. A systematic review and meta-analysis

(2020) Concetta E. Onesti et al.   Expert Review of Anticancer Therapy

4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†

(2018) F Cardoso et al.   ANNALS OF ONCOLOGY